2.5 mg, 5 mg, and 10 mg film-coated tablets
ambrisentan
What Volibris is and what it is used for
Volibris contains the active substance ambrisentan. It belongs to a group of medicines called other antihypertensives (used to treat high blood pressure ).
It is used to treat pulmonary arterial hypertension (PAH) in adults, adolescents, and children aged 8 and over. PAH is high blood pressure in the blood vessels (pulmonary arteries) that transport blood from the heart to the lungs. In people with PAH, these arteries become narrower so the heart has to work harder to pump blood through them. This makes you feel tired, dizzy, and short of breath.
Volibris widens the pulmonary arteries and makes it easier for the heart to pump blood through them. This lowers blood pressure and relieves symptoms.
Volibris can also be used in combination with other medicines used to treat PAH.
What you need to know before you take Volibris
Do not take Volibris
- if you are allergic to ambrisentan, soy, or any of the other ingredients of this medicine (listed in section 6)
- if you are pregnant, if you are planning to become pregnant or if you may become pregnant because you are not using a reliable method of contraception. Read the information under “Pregnancy”
- if you are breastfeeding. Read the information under “Breastfeeding”
- if you have liver disease. Talk to your doctor who will decide if this medicine is suitable for you
- if you have scarring of the lungs, of unknown cause ( idiopathic pulmonary fibrosis ).
Warnings and precautions
Talk to your doctor before taking this medicine:
- if you have liver problems
- if you have anemia (reduced number of red blood cells )
- if you have swollen hands, ankles, or feet caused by fluid retention ( peripheral edema)
- if you have lung disease which means that the veins in the lungs are blocked ( pulmonary venous-occlusive disease).
→ Your doctor will decide if Volibris is suitable for you.
You need to take blood tests regularly
Before you start taking Volibris and regularly while you are taking it, your doctor will take blood tests to check:
- if you have anemia
- and if your liver is working properly.
→ you must submit these regular blood tests as long as you are taking Volibris.
Signs that your liver may not be working as it should include:
- loss of appetite
- nausea
- vomiting
- fever
- stomach ache
- yellowing of the skin or the whites of the eyes (jaundice)
- dark colored urine
- itching of the skin.
If you notice any of these signs:
→ Tell your doctor immediately.
Children
Do not give this medicine to children under 8 years of age as safety and efficacy are not known in this age group.
Other medicines and Volibris
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
If you start taking ciclosporin A (a medicine used after transplantation or to treat psoriasis ), your doctor may need to adjust your dose of Volibris.
If you are taking rifampicin (an antibiotic used to treat serious infections ), your doctor will monitor you more frequently when you start taking Volibris.
If you are taking other medicines used to treat PAH (eg iloprost, epoprostenol, sildenafil) your doctor may need to monitor you more often.
→ Tell your doctor or pharmacist if you are taking any of these medicines.
Pregnancy
Volibris can harm the unborn baby if you become pregnant before, during, or shortly after treatment.
→ If it is possible that you could become pregnant, you should use reliable contraception while taking Volibris. Discuss this with your doctor.
→ Do not take Volibris if you are pregnant or planning to become pregnant.
→ If you become pregnant or suspect you may be pregnant while taking Volibris, contact your doctor immediately.
If you are a woman and could become pregnant, your doctor will ask you to do a pregnancy test before you start taking Volibris and regularly while you are taking Volibris.
Breast-feeding
It is not known whether the active substance in Volibris can pass into breast milk.
→ Do not breastfeed while taking Volibris. Discuss this with your doctor.
Fertility
If you are a man and take Volibris, there may be a risk that Volibris reduces the number of sperm. Talk to your doctor if you have any questions about this.
Driving ability and use of machinery
Volibris can cause side effects, such as low blood pressure, dizziness, and fatigue (see section 4) which can affect your ability to drive or use machines. The symptoms of your illness may also make you less fit to drive or use machinery.
→ Do not drive a vehicle or use machinery if you do not feel well.
Volibris contains lactose
Volibris tablets contain small amounts of sugar called lactose. If your doctor has told you that you have an intolerance to certain sugars:
→ Consult your doctor before taking this medicine.
Volibris contains lecithin that comes from soy
If you are allergic to soya, do not take this medicine (see section 2 “Do not take Volibris”).
Volibris 5 mg and 10 mg tablets contain a dye called Allura red AC aluminum lake (E129)
This can cause allergic reactions (see section 4).
Volibris contains sodium
This medicine contains less than 1 mmol (23 mg) of sodium per tablet, i.e. is almost “sodium-free”.
How to take Volibris
Always use this medicine as directed by your doctor or pharmacist. Ask your doctor or pharmacist if you are unsure.
How much Volibris you should take
Adults
The usual dose of Volibris is one 5 mg tablet once a day. The doctor may decide to increase the dose by one to 10 mg once a day.
If you are taking cyclosporine A, do not take more than one 5 mg tablet of Volibris once a day.
Young people and children aged 8 to younger than 18 years
The usual starting dose of Volibris | |
Weighs 35 kg or more | One 5 mg tablet once daily |
Weighs at least 20 kg and less than 35 kg | One 2.5 mg tablet once daily |
The doctor may decide to increase the dose. Children must come to their regular doctor’s appointments because the dose may need to be adjusted as they get older or gain weight.
When taking ciclosporin A at the same time, the dose of Volibris for adolescents and children weighing less than 50 kg will be limited to 2.5 mg once daily or 5 mg once daily if they weigh 50 kg or more.
How to take Volibris
It is best to take the tablet at the same time each day. Swallow the tablet whole with a glass of water. The tablet should not be split, crushed, or chewed. You can take Volibris with or without food.
Removing a tablet from a blister card (5 mg and 10 mg tablets only)
The tablets are supplied in special packaging to prevent children from taking them out.
Volibris 2.5 mg is packaged in a can, not blister cards.
If you have taken too much Volibris
If you take too many tablets, there is a greater risk of side effects such as headache, flushing, dizziness, nausea, or low blood pressure, which can cause dizziness.
→ Ask your doctor or pharmacist for advice if you take more tablets than prescribed.
If you forget to take Volibris
If you forget to take a dose of Volibris, take it as soon as possible. Then continue taking the medication as prescribed.
→ Do not take a double dose to make up for the missed dose.
If you stop using Volibris
Volibris is a treatment that you must continue to take to control your PAH.
→ Do not stop taking Volibris without your doctor’s agreement.
If you have any further questions about this medicine, ask your doctor or pharmacist.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects are
Tell your doctor if you get any of the following :
Allergic reactions
This is a common side effect that may affect up to 1 in 10 users. You may develop a rash or itching and swelling (usually of the face, lips, tongue, or throat), which may cause difficulty in breathing or swallowing.
Swelling ( edema ), especially of the ankles and feet
This is a very common side effect that may affect more than 1 in 10 users.
Heart failure
This is because the heart is not pumping out enough blood. This is a common side effect that may affect up to 1 in 10 users. Symptoms include:
- respiratory distress
- extreme fatigue
- swollen ankles and legs.
Decreased number of red blood cells ( anemia )
This is a very common side effect that may affect more than 1 in 10 users. Sometimes this requires a blood transfusion. Symptoms include:
- fatigue and weakness
- respiratory distress
- general malaise.
Low blood pressure ( hypotension )
It is a common side effect that may occur in up to 1 in 10 users. Symptoms include:
- dizziness.
→ Tell your doctor immediately if you (or your child) get these side effects or if they occur suddenly after you (or your child) have used Volibris.
You must have regular blood tests to check if you have anemia and that your liver is working properly. Make sure you have also read the information in section 2 under “You need to have regular blood tests” and “Signs that your liver may not be working as it should”.
Other side effects ar
Very common (may affect more than 1 in 10 users)
- headache
- dizziness
- palpitations (rapid or irregular heartbeats)
- shortness of breath that worsens soon after starting treatment with Volibris
- runny or stuffy nose, congestion, or pain in the sinuses
- nausea
- diarrhea
- fatigue.
In combination with tadalafil (another drug against PAH)
In addition to the above:
- flushing (redness of the skin)
- vomiting
- chest pain/discomfort.
Common (may affect up to 1 in 10 users)
- blurred vision or other vision changes
- fainting
- abnormal results on blood tests for liver function
- Runny nose
- constipation
- stomach ache
- chest pain or discomfort
- flushing (redness of the skin)
- vomiting
- feeling of weakness
- nosebleed
- rash.
In combination with tadalafil (another drug against PAH)
In addition to the above, (except abnormal liver function values:
- tinnitus (ringing in the ears).
Uncommon (may affect up to 1 in 100 users)
- liver damage
- inflammation of the liver caused by the body’s immune system ( autoimmune hepatitis ).
In combination with tadalafil
- sudden hearing loss.
Side effects on children and adolescents
These are expected to be similar to adults.
How Volibris should be stored
Keep this medicine out of the sight and reach of children.
Use before the expiry date stated on the packaging after EXP.
The expiration date is the last day of the specified month.
No special storage instructions.
Medicines must not be thrown into the drain or among the household waste. Ask the pharmacist how to dispose of medicines that are no longer used. These measures will help to protect the environment.
Contents of the packaging and other information
Contents declaration
The active substance is ambrisentan
Each film-coated tablet contains 2.5 mg, 5 mg, or 10 mg of ambrisentan.
For 2.5 mg tablets:
Other ingredients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, talc, titanium dioxide (E171), macrogol, and lecithin (soy) (E322).
For 5 mg and 10 mg tablets:
Other ingredients are lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, talc, titanium dioxide (E171), macrogol, lecithin (soya) (E322) and Allura red AC aluminum lacquer (E129).
Appearance and package sizes of the medicine
Volibris 2.5 mg film-coated tablet (tablet) is a white, 7 mm round, convex tablet debossed with “GS” on one side and “K11” on the other side.
Volibris 5 mg film-coated tablet (tablet) is a 6.6 mm light pink, square, convex tablet debossed with “GS” on one side and “K2C” on the other side.
Volibris 10 mg film-coated tablet (tablet) is a 9.8 mm x 4.9 mm dark pink, oval, convex tablet debossed with “GS” on one side and “KE3” on the other side.
Volibris is available as 2.5 mg film-coated tablets in cans. Each jar contains 30 tablets.
Volibris is available as 5 mg and 10 mg film-coated tablets in single-dose blister packs of 10×1 or 30×1 tablets.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
GlaxoSmithKline (Ireland) Limited
12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland
Manufacturer
GlaxoSmithKline Trading Services Limited
12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland
For further information about this medicinal product, contact the representative of the marketing authorization holder:
België/Belgique/BelgienGlaxoSmithKline Pharmaceuticals sa/nvTel/Tel: + 32 (0) 10 85 52 00 | LithuaniaGlaxoSmithKline (Ireland) LimitedTel: + 370 80000334 |
BulgariaGlaxoSmithKline (Ireland) LimitedTel.: + 359 80018205 | Luxembourg/LuxembourgGlaxoSmithKline sa/nvBelgique/BelgiumTel/Tel: + 32 (0) ) 10 85 52 00 |
Czech RepublicGlaxoSmithKline s.r.oPhone: + 420 222 001 111cz.info@gsk.com | MagyarországGlaxoSmithKline (Ireland) LimitedTel.: + 36 80088309 |
DenmarkGlaxoSmithKline Pharma A/SPhone: + 45 36 35 91 00dk-info@gsk.com | MaltaGlaxoSmithKline (Ireland) LimitedPhone: + 356 80065004 |
DeutschlandGlaxoSmithKline GmbH & Co. KGTel.: + 49 (0)89 36044 8701product.info@gsk.com | The NetherlandsGlaxoSmithKline BVPhone: + 31 (0) 33 2081100 |
EstoniaGlaxoSmithKline (Ireland) LimitedPhone: + 372 8002640 | NorwayGlaxoSmithKline iPhone: + 47 22 70 20 00 |
GreeceGlaxoSmithKline Μονοπροσωπη AEBETel: + 30 210 68 82 100 | AustriaGlaxoSmithKline Pharma GmbHTel: + 43 (0)1 97075 0at.info@gsk.com |
SpainGlaxoSmithKline, SAPhone: + 34 900 202 700es-ci@gsk.com | PolishGSK Services Sp. z o. oTel.: + 48 (0)22 576 9000 |
FranceLaboratory GlaxoSmithKlineTel: + 33 (0)1 39 17 84 44diam@gsk.com | PortugalGlaxoSmithKline – Produtos Farmacêuticos, Lda.Phone: + 351 21 412 95 00FI.PT@gsk.com |
HrvatskaGlaxoSmithKline (Ireland) LimitedPhone: + 385 800787089 | RomaniaGlaxoSmithKline (Ireland) LimitedPhone: + 40 800672524 |
IrelandGlaxoSmithKline (Ireland) LimitedPhone: + 353 (0)1 4955000 | SlovenijaGlaxoSmithKline (Ireland) Limited.Phone: + 386 80688869 |
IcelandVistor hf.Telephone: + 354 535 7000 | Slovenian RepublicGlaxoSmithKline (Ireland) LimitedPhone: + 421 800500589 |
ItalyGlaxoSmithKline SpAPhone: + 39 (0)45 7741 111 | Finland/FinlandGlaxoSmithKline OyPhone/Tel: + 358 (0)10 30 30 30 |
CyprusGlaxoSmithKline (Ireland) LimitedTel: + 357 80070017 | SwedenGlaxoSmithKline ABPhone: + 46 (0)8 638 93 00info.produkt@gsk.com |
LatviaGlaxoSmithKline (Ireland) LimitedPhone: + 371 80205045 | United Kingdom (Northern Ireland)GlaxoSmithKline (Ireland) LimitedPhone: + 44 (0)800 221441customercontactuk@gsk.com |